-
-
-
-
-
-
About Genesis Therapeutics
Related fields
Categories
Related News
Dotmatics aims to speed drug development, break data silos with Geneious Luma
Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More Even as enterprises across sectors explore how to integrate generative AI, it's clear that biomedical research and the sciences are among the areas that could benefit most -- as highlighted in the recent Nobel Prizes in Chemistry and Physics awarded to AI researchers. Now Dotmatics, a leader in research and development scientific software, wants to give drug researchers the power of AI to speed up their development of new, life-saving and improving drugs. Today, the Boston-based company launches Geneious Luma, a powerful new bioinformatics solution for antibody discovery, built on its Luma Scientific Intelligence Platform. Geneious Luma is designed to streamline the process of biologic therapeutic discovery by integrating advanced sequence analysis, data management, and AI-powered automation. This release marks the first of several multimodal solutions aimed at transforming scientific research and accelerating the discovery of new therapies. Thomas Swalla, CEO of Dotmatics, explained the benefit of Geneious Luma in a recent video interview with VentureBeat: "The problem we're solving is that discovering new molecules and drugs has become increasingly complicated. It takes over a decade to bring a drug to market and costs anywhere from two to six billion dollars." With Geneious Luma, Dotmatics addresses the challenges of fragmented workflows and siloed data in biologic research. The platform integrates key tools like Geneious Prime and Geneious Biologics to streamline antibody sequence discovery and protein engineering, from in-silico design to wet-lab experimentation and decision support. As Swalla noted, "Dotmatics is addressing the fragmentation and complexity of drug discovery. The promise of new therapies, like cell and gene therapies, is tremendous, but the science is really complicated. We're working to pull all these areas together." As such, it goes up against other AI drug discovery platforms such as VeriSIM Life and Platforma.bio, but can also integrate data from them -- with the scientist users' permission, of course. Antibody research Dotmatics supports over 2 million scientists and 10,000 customers in 180 countries. Its solutions streamline R&D processes by connecting science, data, and decision-making. Dotmatics' team of over 850 employees operates globally, with its principal office in Boston. Geneious Luma builds upon the capabilities of the Luma platform to provide seamless bioinformatics solutions tailored specifically for antibody and protein engineering. The platform is designed to accelerate workflows across therapeutic modalities, including antibodies, antibody-drug conjugates (ADCs), RNA and gene therapies, and vaccines. t enables researchers to work more efficiently by automating complex data processes and centralizing all relevant data into a unified workspace. By incorporating tools like Geneious Prime, which offers industry-leading cloning and sequence analysis, and Geneious Biologics, which enhances antibody sequence discovery, Geneious Luma ensures that researchers have the advanced capabilities needed to tackle the complexities of antibody engineering. Swalla further emphasized how the platform enhances research efficiency: "With our new product, Luma, you can pull together massive datasets across these fragmented areas of science, putting language models on top of them to speed up the discovery of new molecules and drugs." Advances in AI The flexibility of Geneious Luma is one of its greatest strengths. It leverages AI and machine learning to automate workflows, enabling scientists to manage complex biological data with greater accuracy and speed. Michael Swartz, Chief Strategy Officer at Dotmatics, told VentureBeat in the same video interview call how the platform adapts to real-time needs: "Our software is able to adapt in near real-time to whatever the scientist decides to do. Luma can call out to external models like [DeepMind's] AlphaFold to assist, which hasn't been possible before." But that's just one of many external AI tools and resources that users can pipe into Geneious Luma. "Today, we enable AI models through Luma, but our customers can pick whichever model they want and put it closest to the data in their life sciences ecosystem," Swalla clarified. "We know we have to partner with companies that bring models and help with accelerated compute because that's what will make AI in drug discovery economically feasible." In addition to AI-assisted discovery, Geneious Luma incorporates powerful tools like Luma Lab Connect, which automates data ingestion from lab instruments such as flow cytometers and mass spectrometers, allowing researchers to efficiently collect, process, and analyze data from multiple sources. "When you think about instrument integration, it's not static," Swartz explained. "We grab the data off the software and deliver it precisely at the right time and in the right organizational framework, in a frictionless way." Solving for siloed data In the increasingly complex landscape of therapeutic discovery, the ability to manage large and diverse datasets is crucial. Geneious Luma offers a solution to one of the biggest hurdles in life sciences today -- siloed and unstructured data. Swalla commented, "The real issue in life sciences isn't a lack of AI models; it's that the data isn't big enough, structured enough, or trusted enough to train those models. That's the problem we're trying to solve with Luma." By integrating all the necessary tools and workflows into a single, cohesive platform, Geneious Luma enables researchers to overcome these data challenges, fostering collaboration across teams and speeding up the discovery process. Beyond antibodies While the initial focus of Geneious Luma is on antibody and protein engineering, Dotmatics plans to extend the platform's capabilities into other areas of biologic research, such as CAR-T therapies, CRISPR, and RNA-based medicine. Swalla sees this as a tremendous opportunity: "In this industry, people are still using paper and pencil, and there are companies that haven't moved to the cloud. We're 15 years behind in terms of tech adoption, which is a huge opportunity for us." The flexibility of the Geneious Luma platform ensures that it can be adapted for various therapeutic discovery processes, driving efficiency across the industry. Dotmatics is also exploring opportunities to extend the platform into other scientific domains, including material science and agritech. Geneious Luma is available now as part of the Dotmatics Luma platform, with further enhancements planned for the future. As Dotmatics continues to innovate, the company aims to push the boundaries of drug discovery through integrated bioinformatics and AI-driven research.
VentureBeat
Tue, 22 Oct, 2:34 PM UTC
Genedata: Powering Biopharma AI
In the age of AI and machine learning, data is more valuable than ever before. However, biopharma companies often lack the high-quality, structured data needed to power advanced models to generate business- and science-accelerating insights. That's where Genedata comes in. Founded in 1997 by Dr. Othmar Pfannes, Genedata develops scalable enterprise software that produces AI-ready data, ensuring maximum efficiency and ease of collaboration. Genedata's philosophy centers on building a high-quality structured data foundation. New robotic systems and laboratory automation are dramatically increasing the amount of experimental data-creating a new need for a truly scalable platform that can structure and manage this exponentially growing volume. Only with a fully integrated data infrastructure can researchers extract the patterns they need to guide future R&D projects, and this what Genedata is best-in-class at providing, with solutions covering the entire drug development life cycle. Customers include all top 25 biopharma companies, many innovative biotech organizations, CROs/CDMOs, not-for-profit institutes and academic organizations. In July 2024, Genedata joined Danaher. By integrating Genedata's advanced software capabilities and biologics R&D data expertise into our life sciences and diagnostics applications, we are enhancing our internal capabilities and enabling our customers to leverage AI from discovery through manufacturing and commercialization. Ultimately, this integration will accelerate the development of new medicines.
Market Screener
Fri, 22 Nov, 4:06 PM UTC
Geneial Secures Major Contract with RENCI and NHLBI to Partner with ARPA-H to Transform Biomedical Data Standardization with Advanced AI
HOUSTON, Oct. 31, 2024 /PRNewswire/ -- Geneial, a company advancing private, community-led genetic medicine, has been awarded a one-year pilot project through National Heart, Lung, and Blood Institute's BioData Catalyst® (BDC) program and the Renaissance Computing Institute (RENCI) to advance AI tools to streamline the complex process of transforming biomedical data into analysis-ready formats. Geneial will collaborate with RENCI, NHLBI BioData Catalyst (BDC), and performers from the Advanced Research Projects Agency for Health (ARPA-H) Biomedical Data Fabric (BDF) Toolbox program to unlock new possibilities for precision medicine research and implementation on a broad scale. Geneial expands into generative AI space to simplify biomedical data management, reducing costs and improving access. As healthcare research relies increasingly on mapping fragmented datasets to standardized and interoperable data models, Geneial's new AI tools will optimize and automate this process, which currently requires extensive manual effort and significant financial investment. Geneial's technology will offer flexible, efficient conversion to current standards -- such as the Global Alliance for Genomics and Health (GA4GH) Phenopackets format -- while anticipating future data needs and supporting adaptable, evolving standards. "Data standardization remains a significant challenge in precision medicine," said Dr. Adam Hansen, CEO of Geneial. "Our collaboration with ARPA-H, NHLBI, and RENCI directly addresses this critical bottleneck, enabling researchers to focus on groundbreaking discoveries rather than laborious data management. By advancing tools that meet today's needs and adapt to tomorrow's, we're substantially reduce data wrangling costs as we enhance the utility of biomedical data." This work aligns with Geneial's broader vision of a global, privacy-preserving data exchange, one that allows individuals and data custodians to maintain control while connecting researchers, drug developers, and healthcare systems with harmonized, high-quality data. It marks a significant expansion of the business into AI-driven data standardization, while reinforcing Geneial's commitment to accelerating progress in genomic medicine, making it easier for researchers to derive insights that can lead to better, more inclusive healthcare. Expanding Expertise in AI and Healthcare Innovation In alignment with its growth strategy, Geneial has recently expanded its team with notable experts in AI and healthcare data. Joshua Proulx, formerly Chief Data Scientist at Safe & Reliable Healthcare (acquired by Vizient) and previously its Chief Technology Officer, brings extensive experience in healthcare data reliability and safety. Bryce Daines, Ph.D., formerly Chief Technology Officer at Modulus Therapeutics, brings deep expertise in high-throughput AI applications for biomedical research. Together, Proulx, Daines and other new team members strengthen Geneial's position as a forward-thinking partner in healthcare data innovation. Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. About RENCI RENCI (Renaissance Computing Institute) develops and deploys advanced technologies to enable research discoveries and practical innovations. RENCI partners with researchers, government, and industry to engage and solve the problems that affect North Carolina, our nation, and the world. An institute of the University of North Carolina at Chapel Hill, RENCI was launched in 2004 as a collaboration involving UNC Chapel Hill, Duke University, and North Carolina State University. About Geneial Geneial is committed to creating equitable health futures by building secure, human-centered solutions for biomedical data. As Geneial expands into AI-driven data standardization, it empowers data owners and researchers with tools that unlock the value of harmonized data, driving forward precision medicine and improving access to transformative insights. View original content to download multimedia:https://www.prnewswire.com/news-releases/geneial-secures-major-contract-with-renci-and-nhlbi-to-partner-with-arpa-h-to-transform-biomedical-data-standardization-with-advanced-ai-302292177.html SOURCE Geneial Market News and Data brought to you by Benzinga APIs
Benzinga
Thu, 31 Oct, 4:13 PM UTC
RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases
BENGALURU, India, Dec. 10, 2024 (GLOBE NEWSWIRE) -- RenaissThera Private Limited ("RenaissThera") a pioneering Bengaluru-based biotechnology company, has successfully closed its seed funding round backed by angel investors. This funding will accelerate the development of novel small-molecule therapies targeting GLP-1 and GIP receptors for Cardio-metabolic (CM) diseases, with an emphasis on diabetes and obesity. The company aims to address critical health challenges in underserved populations globally through affordable and transformative solutions. RenaissThera is revolutionizing the fight against cardio-metabolic diseases like diabetes and obesity through its AI-powered Innovation Platform, leveraging Generative AI (GenAI) and machine learning to rapidly identify and optimize small molecules for targeted therapies. Mr. Sudhir Nagarajan, Managing Director, said, "We thank all the investors in this round for their support and belief in our team and the promise of RenaissThera in delivering innovative medicines." With the successful close of its seed funding round, CEO Dr. Ramkesh Meena stated, "This milestone enables us to scale up and validate our early-stage pipeline in pre-clinical proof-of-concept studies and get ready for IND filing next year, propelling us closer to delivering life-changing, affordable therapies that address critical gaps in care." This innovative approach combines scientific rigor and efficiency to reduce development timelines and costs while improving patient outcomes worldwide. About RenaissThera. RenaissThera, based in Bengaluru, India is a biotechnology company dedicated to developing affordable, novel small-molecule targeted therapies leveraging AI platforms. Our goal is to innovate for underserved populations and bridge the gaps in novel therapy access worldwide. We focus on high-unmet-need areas of prevalent diseases in key therapy areas such as Cardio-metabolic including diabetes and obesity indications. Leveraging our Innovation Platform powered by GenAI tools, we identify small-molecule therapies for proven pathways, ensuring cutting-edge solutions for patients. For more information, visit www.renaissthera.com. Contact: Lakshmi Ramakrishna Email id - lramakrishna@renaissthera.com Mob. no. - +91- 9176940015 Market News and Data brought to you by Benzinga APIs
Benzinga
Tue, 10 Dec, 2:11 PM UTC
Indegene Launches Cortex, A Fit-For-Purpose Generative AI Platform, Verticalized For The Life Sciences Industry
Indegene, a digital-first, life sciences commercialization company, launched Cortex, a fit-for-purpose Generative AI (GenAI) platform, verticalized for the life sciences industry. As a life sciences-specialist knowledge engineering and multi- agent orchestration platform, Cortex by Indegene enables life sciences leaders to adopt and scale this transformative technology with enterprise-grade governance. This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain, making medical writing more effective and efficient, and accelerating Medical-Legal-Regulatory (MLR) reviews. Its knowledge engineering interface codifies Indegene's 25+ years of subject matter expertise into advanced knowledge graphs using a domain- friendly interface. Moreover, its fit-for-purpose agents can be configured with any preferred Large Language Model (LLM) and evolve as LLM state-of-the-art improves. Further, its multi-agent orchestration enables use case-specific applications for enterprise-wide system integration. Together, these yield more reliable, accurate and trustworthy outcomes from LLM-based agents with substantially faster turnaround times and better ROI at lower risk, relative to industry-agnostic platforms. This GenAI platform's embedded domain knowledge graphs capture nuances and details of life sciences' processes and tasks and benefit from continuous improvement. "Life sciences leaders believe in GenAI's potential to transform and modernize their commercialization processes," said Manish Gupta, Chairperson and CEO, Indegene. "They also demand an enterprise-grade platform that assures them of the security, governance, scalability and business value essential to adopting technology across the enterprise. With this GenAI platform, we codify our 25+ years of practitioner experience letting life sciences leaders make the most of this transformative technology." Tarun Mathur, CTO, Indegene, added, "Life sciences leaders demand an AI infrastructure that adapts to new business models, processes and experiences. Our new GenAI platform empowers them to develop their own intellectual property (IP), leveraging Indegene's technology and knowledge engineering practices. We look forward to supporting the wide number of use cases they apply this exciting technology to and the value they realize in the process." Leading industry analysts recognize Indegene's bold vision and market impact in adopting and scaling GenAI in the life sciences industry. HFS Research, a global business research consultancy recognized Indegene as a Horizon 3 OneEcosystem Exponential Leader for leveraging GenAI to collaborate across the life sciences and healthcare ecosystem to improve health outcomes, enhance stakeholder experience and optimize costs. Everest Group, a leading research and advisory firm identified Indegene as a Front- Runner for scaling GenAI, capturing industry-specific use cases, building partnerships and delivering value. To learn more about Cortex and how Indegene is enabling life sciences leaders to realize GenAI's potential, please visit www.indegene.com/what-we-do/cortex
CXOToday.com
Mon, 24 Feb, 3:34 PM UTC
Similar products
Your one-stop AI hub
The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
© 2025 Triveous Technologies Private Limited
